data + articles · 2 listed
newest 2009spec sheet10 rows
Xaliproden (SR57746A) is a synthetic 5-HT1A serotonin receptor agonist that also shows neurotrophic, NGF-like activity (nerve growth factor supports the survival and repair of neurons). It was investigated as a possible neuroprotective drug in amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and chemotherapy-induced peripheral neuropathy. Trials showed modest signals but it was not approved for these uses.
- 5-HT1A agonism
- NGF-like neurotrophic activity
- Studied for nerve protection
- Generally tolerated in trials
- Dizziness
- Fatigue
- Gastrointestinal upset
Mechanism
Xaliproden acts as an at the receptor, and separately it promotes neurotrophic signaling in a way that mimics nerve growth factor, encouraging neurite outgrowth and neuronal survival in preclinical models. This dual profile, serotonergic plus growth-factor-like, is the basis for its study in neurodegenerative and neuropathic conditions where nerve loss or damage is central. Its clinical effect was investigated as slowing nerve degeneration rather than acting as a stimulant or symptomatic drug.
receptor fingerprint
receptoragonist
-like neurotrophic signalingenhancer
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
In trials xaliproden was generally tolerated but could cause dizziness, fatigue, and gastrointestinal upset, consistent with its serotonergic activity, and combining serotonergic agents always raises theoretical serotonin-toxicity concerns. Because it never reached routine clinical use, its long-term safety in the general population is not established. Not medical advice.
Subjective profileweighing the evidence above
Never earned its place. Pairing 5-HT1A agonism with NGF-like activity was a reasonable idea, but the signals in ALS and neuropathy trials stayed modest, it was never approved, and long-term safety was never established. Nothing here for nootropic use and nothing to buy.
Resources
This entry is here for reference.
Research
- 1.SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases
- 2.What we have learned from the Xaliproden Sanofi-aventis trials
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is xaliproden?
A 5-HT1A agonist with nerve growth factor-like activity, studied as a neuroprotective drug in ALS and neuropathy.
Was it approved?
No; despite modest trial signals it was not approved for its studied indications.
How does it protect nerves?
Through serotonergic 5-HT1A activity combined with neurotrophic, NGF-mimicking signaling that supports neuron survival and repair.
Limitations of the evidence
- Unproven clinical benefit
Adverse effects
- Dizziness
- Fatigue
- Gastrointestinal upset